Stay updated with breaking news from Chau Cheng. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ...
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 -- Immunovant, Inc. , a...
NEW YORK, Oct. 02, 2023 -- Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its...
NEW YORK, Sept. 27, 2023 -- Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an...
NEW YORK, Sept. 25, 2023 -- Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report...